Providing a resource (Clinical Study Coordinator) with particular expertise in effectively addressing NIH, IRB and HIPAA policies and reporting requirements concerning confidentiality, inclusion of women, children and ethnic/minority participation in clinical studies, data and safety monitoring requirements; and educational requirements for the protection of human research participants. As recognized recently, perhaps the least appreciated (but most important) barrier to translational and clinical research is the limited availability of administrative support for translation at most academic medical Centers [1; 2]. With the increasing regulatory requirements for translational and clinical research, worthwhile studies are currently being abandoned simply because of the burden of regulatory compliance [1]. The main objective of the clinical component of the Yale Liver Center is to alleviate this regulatory burden by providing this resource. This resource is of particular importance for Yale investigators since patients for clinical trials are recruited from both Yale-New Haven Medical Center and from the CT-VA Healthcare System, and each of them have separate IRBs and separate regulatory requirements. Additionally, this resource will maintain a patient, serum and DNA data and aid in the identification (through the clinical and sample databases) and recruitment of subjects for translational and clinical studies. This resource will constitute a bridge between Center basic science investigators and clinical investigators and among clinical investigators. b) Providing a resource (Biostatistician) that provides assistance to basic researchers with clinical study design, particularly for small pilot projects that are the initial step in the translational process. For established clinical investigators using the clinical component, this resource will provide consultation for clinical study/trial development particularly in establishing sample size calculations and advise regarding the most appropriate study design. c) Providing the opportunity for Center members to obtain patient data and clinical (serum, liver, DNA) samples needed for their research, including data regarding the number of patients available to evaluate study feasibility and estimated times for patient recruitment into clinical trials. This service will be provided through the Patient Database and the Serum, Liver Biopsy and DNA banks that will be maintained by the Clinical Study Coordinator.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK034989-22
Application #
7103635
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2005-09-01
Budget End
2006-08-31
Support Year
22
Fiscal Year
2005
Total Cost
$187,647
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Madiraju, Anila K; Qiu, Yang; Perry, Rachel J et al. (2018) Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo. Nat Med 24:1384-1394
Schmitz, Corinna; Noels, Heidi; El Bounkari, Omar et al. (2018) Mif-deficiency favors an atheroprotective autoantibody phenotype in atherosclerosis. FASEB J 32:4428-4443
Pan, Qiong; Zhang, Xiaoxun; Zhang, Liangjun et al. (2018) Solute Carrier Organic Anion Transporter Family Member 3A1 Is a Bile Acid Efflux Transporter in Cholestasis. Gastroenterology 155:1578-1592.e16
Jakab, Sofia Simona; Garcia-Tsao, Guadalupe (2018) Screening and Surveillance of Varices in Patients With Cirrhosis. Clin Gastroenterol Hepatol :
Fiorotto, Romina; Amenduni, Mariangela; Mariotti, Valeria et al. (2018) Src kinase inhibition reduces inflammatory and cytoskeletal changes in ?F508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy. Hepatology 67:972-988
Sari, Sinan; Dalgic, Buket; Muehlenbachs, Atis et al. (2018) Prototheca zopfii Colitis in Inherited CARD9 Deficiency. J Infect Dis 218:485-489
Yu, Dongke; Cai, Shi-Ying; Mennone, Albert et al. (2018) Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents. Liver Int 38:1128-1138
Garcia-Tsao, Guadalupe (2018) Regression of HCV cirrhosis: Time will tell. Hepatology 67:1651-1653
Hung, Adelina; Garcia-Tsao, Guadalupe (2018) Acute kidney injury, but not sepsis, is associated with higher procedure-related bleeding in patients with decompensated cirrhosis. Liver Int 38:1437-1441
Kaffe, Eleanna; Fiorotto, Romina; Pellegrino, Francesca et al. (2018) ?-Catenin and interleukin-1?-dependent chemokine (C-X-C motif) ligand 10 production drives progression of disease in a mouse model of congenital hepatic fibrosis. Hepatology 67:1903-1919

Showing the most recent 10 out of 763 publications